GSK-3β inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression
- 3 September 2004
- journal article
- Published by Elsevier in Experimental Cell Research
- Vol. 300 (2) , 354-364
- https://doi.org/10.1016/j.yexcr.2004.08.001
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3‐kinase activationJournal of Neurochemistry, 2003
- Glycogen synthase kinase-3β is highly activated in nuclei and mitochondriaNeuroReport, 2003
- Characterization of p53-mediated Up-regulation of CD95 Gene Expression upon Genotoxic Treatment in Human Breast Tumor CellsPublished by Elsevier ,2003
- Expression, localization, and activity of glycogen synthase kinase 3β during mouse skin tumorigenesisMolecular Carcinogenesis, 2002
- Dysregulation of glycogen synthase kinase-3β signaling in hepatocellular carcinoma cellsHepatology, 2002
- Death and anti-death: tumour resistance to apoptosisNature Reviews Cancer, 2002
- ATM Mediates Phosphorylation at Multiple p53 Sites, Including Ser46, in Response to Ionizing RadiationJournal of Biological Chemistry, 2002
- Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3β and attenuated by lithiumBrain Research, 2001
- The multifaceted roles of glycogen synthase kinase 3β in cellular signalingPublished by Elsevier ,2001
- Insulin and IGF-1 stimulate the β-catenin pathway through two signalling cascades involving GSK-3β inhibition and Ras activationOncogene, 2001